RxDoctor Payments Data

Hassan Attique, MD

Nephrology · Fargo, NDNPI 1033562525

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 96.4% of the total across 29 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 9 manufacturers, the largest accounting for just 21.9% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $452 and has fallen 89.5% since, to $48 in 2024.

$679in general payments, 2019–2025

Across 29 payments — averaging $23.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Vifor Pharma, Inc.$149
  • Bayer$131
  • Aurinia Pharma U.S., Inc.$102
  • Otsuka America Pharmaceutical, Inc.$89
  • Amgen$64
  • GSK$50
  • plus $95 from 3 others

What the payments were for

  • Food & beverage$65596%
  • Education$254%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$679 in reported general payments places this provider in the 70th percentile of 22 nephrology providers in North Dakota.

See all nephrology providers in North Dakota

Medicare billing

Part B allowed, 2024
$205,145
Medicare patients
369
Services billed
1,549

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol34$31,002
JardianceEmpagliflozin15$18,342
ClinisolParenteral Amino Acid 15% No.521$3,954
Calcium Acetate84$3,596
Potassium Citrate ErPotassium Citrate16$2,183
Sevelamer Carbonate28$2,131
Bumetanide41$1,408
Torsemide66$1,336
Nifedipine ErNifedipine42$1,229
Tamsulosin Hcl21$853
Losartan Potassium83$764
Allopurinol77$663
Calcitriol45$615
Carvedilol36$423
Metolazone21$295

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$42$31,00234 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 22 nephrology providers in North Dakota.

Other nephrology in Fargo

See the full list for North Dakota

Where these figures come from

Is this you, or does something look wrong? →